ArticleRespiratory research2024
Development and validation of a Prediction Model for Chronic Thromboembolic Pulmonary Disease.
Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of a lung perfusion automated quantitative model based on dual-energy CT pulmonary angiography in patients with chronic pulmonary thromboembolism.Insights into imaging · 2025Article
- The Aftermath of Pulmonary Embolism: Are Residual Thrombi Clinically Significant?Diagnostics (Basel, Switzerland) · 2025Review
- Value of Optimal Follow-up in Patients with Pulmonary Embolism (OFUPE): Study Protocol for a Prospective Randomized Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAcute pulmonary embolism (APE) is a critical disease with a high mortality rate, some of the surviving patients may develop chronic thromboembolic pulmonary disease (CTEPD), which affects the patient's prognosis. However, the research on the early diagnosis of CTEPD is limited. This study aimed to establish a prediction model for earlier identification of CTEPD.
methodsThis prospective study included 464 consecutive patients with APE confirmed between January 2020 and September 2023, at 7 centers from China. After follow-up for at least 3 months, the patients were divided into the CTEPD and non-CTEPD groups based on symptoms and computed tomography pulmonary angiography (CTPA) or pulmonary ventilation perfusion (V/Q) scans showing residual thrombosis. The independent risk factors for CTEPD were identified via univariate and multivariate logistic regression analyses. Next, a nomogram of predictive model was established, and validation was completed via decision curve analysis (DCA) and receiver operating characteristic curve analysis.
resultIn total, 130 (28%) patients presented with CTEPD, 17% (22/130) of CTEPD patients developed chronic thromboembolic pulmonary hypertension (CTEPH). Based on the multivariate analysis, a time interval from symptoms onset to diagnosis (time-to-diagnosis) ≥ 15 days (95% confidence interval [CI]: 3.392-14.972, p < 0.001), recurrent pulmonary embolism (RPE) (95%CI: 1.560-17.300, p = 0.007), right ventricular dysfunction (RVD) (95%CI: 1.042-6.437, p = 0.040), central embolus (95%CI: 1.776-7.383, p < 0.001) and residual pulmonary vascular obstruction (RPVO) > 10% (95%CI: 4.884-21.449, p < 0.001) were identified as the independent predictors of CTEPD. Then, A prediction model with a C-index of 0.895 (95% CI 0.863-0.927) was established for high-risk patients. The nomogram had an excellent predictive performance for earlier identification of CTEPD, with an area under the curve of 0.908 (95%CI: 0.875-0.941) in the training cohort and 0.875 (95%CI: 0.803-0.947) in the validation cohort.
conclusionThe current study established and validated a reliable nomogram for predicting CTEPD, which would assist clinicians identify the high-risk patients for CTEPD earlier.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.